VERTEX PHARMACEUTICALS INC (VX1.DE) Earnings History & Surprises
FRA:VX1 • US92532F1003
390.85 EUR
-10.1 (-2.52%)
Last: Mar 6, 2026, 07:00 PM
Past quarterly earnings results for VERTEX PHARMACEUTICALS INC (VX1.DE), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Release DateMay 4, 2026
PeriodQ1 / 2026
EPS Estimate$4.47
Revenue Estimate3.126B
Last Reported
Release DateFeb 12, 2026
PeriodQ4 / 2025
EPS Reported$5.03
EPS Surprise -2.79%
Revenue Surprise -1.51%
Beat Rate
44%
EPS and Revenuebeats vs estimates
Quarterly Earnings Results
EPS & Revenue History (USD)
Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 5.03 | 5.17 | -2.79% | 26.38% | 3.19B | 3.239B | -1.51% | 9.55% |
| Q3 2025 | 4.80 | 4.65 | 3.12% | 9.59% | 3.076B | 3.114B | -1.21% | 10.99% |
| Q2 2025 | 4.52 | 4.37 | 3.45% | 135.23% | 2.965B | 2.963B | 0.06% | 12.06% |
| Q1 2025 | 4.06 | 4.37 | -7.20% | -14.71% | 2.77B | 2.91B | -4.80% | 2.96% |
| Q4 2024 | 3.98 | 4.11 | -3.07% | -5.24% | 2.912B | 2.836B | 2.68% | 15.66% |
| Q3 2024 | 4.38 | 4.22 | 3.69% | 7.35% | 2.772B | 2.778B | -0.22% | 11.61% |
| Q2 2024 | -12.83 | 3.00 | -527.57% | -429.82% | 2.646B | 2.715B | -2.56% | 6.11% |
| Q1 2024 | 4.76 | 4.14 | 14.85% | 56.07% | 2.691B | 2.63B | 2.30% | 13.30% |
| Q4 2023 | 4.20 | 4.18 | 0.36% | 11.70% | 2.518B | 2.564B | -1.81% | 9.34% |
| Q3 2023 | 4.08 | 4.05 | 0.66% | 1.75% | 2.484B | 2.55B | -2.61% | 6.39% |
| Q2 2023 | 3.89 | 3.96 | -1.75% | 8.06% | 2.493B | 2.468B | 1.02% | 13.52% |
| Q1 2023 | 3.05 | 3.06 | -0.21% | -13.35% | 2.375B | 2.384B | -0.39% | 13.22% |
| Q4 2022 | 3.76 | 3.58 | 4.95% | 11.57% | 2.303B | 2.347B | -1.89% | 11.10% |
| Q3 2022 | 4.01 | 3.72 | 7.89% | 12.64% | 2.334B | 2.271B | 2.79% | 17.65% |
| Q2 2022 | 3.60 | 3.55 | 1.44% | 15.76% | 2.196B | 2.175B | 0.97% | 22.46% |
| Q1 2022 | 3.52 | 3.56 | -1.18% | 18.12% | 2.098B | 2.118B | -0.97% | 21.64% |
| Q4 2021 | 3.37 | 3.37 | 0.13% | 34.26% | 2.073B | 2.043B | 1.45% | 27.32% |
| Q3 2021 | 3.56 | 3.14 | 13.27% | 34.85% | 1.984B | 1.893B | 4.82% | 28.99% |
| Q2 2021 | 3.11 | 2.56 | 21.59% | 19.16% | 1.793B | 1.752B | 2.36% | 17.64% |
| Q1 2021 | 2.98 | 2.74 | 8.66% | 16.41% | 1.724B | 1.69B | 2.03% | 13.81% |
| Q4 2020 | 2.51 | 2.64 | -5.00% | - | 1.628B | 1.616B | 0.73% | - |
| Q3 2020 | 2.64 | 2.39 | 10.49% | - | 1.538B | 1.515B | 1.54% | - |
| Q2 2020 | 2.61 | 2.12 | 23.38% | - | 1.524B | 1.413B | 7.89% | - |
| Q1 2020 | 2.56 | 1.88 | 36.03% | - | 1.515B | 1.313B | 15.39% | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
2
Average EPS beat (4)
-0.85%
Max EPS beat (4)
3.45%
Min EPS beat (4)
-7.20%
Revenue beat statistics
Revenue beat (4)
1
Average Revenue beat (4)
-1.87%
Max Revenue beat (4)
0.06%
Min Revenue beat (4)
-4.80%
Analysis
In the last 4 quarters, VX1.DE has beaten EPS estimates in 2 out of 4 releases
VX1.DE has beaten revenue estimates in 1 out of the last 4 releases
In the last 4 quarters, VX1.DE reported -0.9% below the EPS estimates on average.
In the last 4 quarters, VX1.DE reported -1.9% below the revenue estimates on average.
VERTEX PHARMACEUTICALS INC / VX1.DE Earnings FAQ
When did VERTEX PHARMACEUTICALS INC (VX1.DE) report earnings last quarter?
VERTEX PHARMACEUTICALS INC (VX1.DE) last reported earnings on 2/12/2026.
Did VX1 stock beat earnings estimates in the most recent quarter?
VERTEX PHARMACEUTICALS INC (VX1.DE) missed EPS estimates and missed revenue estimates in the most recent quarter.
What percentage of the time does VX1 stock beat earnings estimates?
In the last 4 quarters, VERTEX PHARMACEUTICALS INC (VX1.DE) has beaten EPS estimates in 2 out of 4 releases.